Country: Canada
Language: English
Source: Health Canada
NAPROXEN; ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM)
MYLAN PHARMACEUTICALS ULC
M01AE52
NAPROXEN AND ESOMEPRAZOLE
375MG; 20MG
TABLET (IMMEDIATE AND DELAYED-RELEASE)
NAPROXEN 375MG; ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) 20MG
ORAL
60/100/500
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0252870001; AHFS:
APPROVED
2017-02-10
_ _ _MYLAN-NAPROXEN / ESOMEPRAZOLE MR (Naproxen / Esomeprazole Modified Release Tablets) _ _Page 1 of 65_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr MYLAN-NAPROXEN / ESOMEPRAZOLE MR Naproxen / Esomeprazole (as esomeprazole magnesium) Modified release tablets, 375 mg naproxen / 20 mg esomeprazole and 500 mg naproxen / 20 mg esomeprazole, Oral NSAID and H + , K + -ATPase Inhibitor Mylan Pharmaceuticals ULC 85 Advance Road Etobicoke, Ontario M8Z 2S6 Date of Initial Authorization: FEB 08, 2017 Date of Revision: JUL 04, 2023 Submission Control Number: 273201 _ _ _MYLAN-NAPROXEN / ESOMEPRAZOLE MR (Naproxen / Esomeprazole Modified Release Tablets) _ _Page 2 of 65_ RECENT MAJOR LABEL CHANGES 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 07/2023 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests 07/2023 7 WARNINGS AND PRECAUTIONS, Skin 07/2023 7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations 07/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION . Read the complete document